Sickle Cell Disease (SCD) may lead to several acute and chronic complications and the end-organ damage may be aggravated by co-existing conditions. [1] Among SCD patients, autoimmune disorders, such as autoimmune hepatitis (AIH) or systemic lupus erythematosus, are not infrequent and are difficult to treat due to the high risk of adverse events associated with steroids or other immunosuppressive treatments. [2] [3] [4] Hematopoietic Stem Cell Transplantation (HSCT) is the most consolidated curative therapy for patients with SCD, but benefits and risks in both the short and long term must be carefully considered, taking into consideration disease variability and the recent appearance of new drugs. Despite the progressive broadening of indications for HSCT, [5] the majority of pediatric haematologists still offers it only to patients with a severe phenotype: cerebrovascular disease, recurrent vasoocclusive crises (VOC) or acute chest syndrome not responsive to Hydroxycarbamide, or sickle nephropathy. [6, 7] HSCT is also an option for the management of severe autoimmune disorders such as multiple sclerosis, systemic sclerosis and rheumatoid arthritis, but it has not been previously reported for autoimmune hepatitis. [8] We report a patient with SCD and AIH, both cured after HSCT.
Our patient was diagnosed with HbSS SCD at the age of 4 years when she was hospitalized for severe haemolytic anaemia. At the age of 7 years, Trans-Cranial Doppler (TCD) showed a velocity >200 cm/s in both the middle cerebral arteries and the basilar artery with a normal brain magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA). The patient began a regular blood transfusion program for stroke prevention, which was changed to monthly red cell exchange transfusions (ECA) at the age of 8 years when adequate venous lines could be placed. At the age of 11 years, severe stenosis of the carotid syphon and middle cerebral arteries and moderate stenosis of the anterior cerebral arteries seen on MRA (Fig. 1a) prompted ECA to be scheduled every three weeks to maintain HbS under 30%. At the age of 13 years, MRI/ MRA showed a minimal reduction of arterial stenosis with a concomitant normalization of TCD, which was confirmed two years later. No clinical or subclinical stroke occurred.
At the age of 13 years the patient was hospitalised for cholestatic jaundice (total bilirubin 277.1 µmol/L, conjugated bilirubin 171.2 µmol/L) and elevation of liver enzymes (AST 1188 U/L, ALT 74 U/L and GGT 188 U/L). Liver infection, liver sequestration and disorders of the biliary tree were excluded by appropriate investigations including magnetic resonance cholangio-pancreatography. Anti-nuclear and anti-smooth muscle antibodies resulted positive at a titer of 1:320 and >1:80 respectively, and hypergammaglobulinemia was noticed (IgG 25 g/L). The diagnosis of type I AIH was confirmed by liver histology, which showed portal and peri-portal fibrosis, portal inflammatory infiltrates (mostly constituted of lymphocytes and plasma cells) and focal areas of necrosis (Fig. 2) . Treatment with prednisolone was initiated with prompt normalization of liver enzymes and resolution of cholestasis, and one month later azathioprine was added after having excluded TPMT variants. Steroid treatment was Raffaella Colombatti and Laura Sainati contributed equally to the work. tapered and discontinued 5 months after the diagnosis of AIH but was resumed one month later due to disease relapse. In the following four years, the patient experienced two relapses of AIH, demonstrating the absolute need of constant immunosuppression with steroids and azathioprine. The anti-nuclear and anti-smooth muscle autoantibodies remained persistently positive during follow-up, with a fluctuating titer corresponding to disease activity. Due to the appearance of recurrent and severe VOCs while assuming steroids, exchange transfusions were performed every 18-20 days. At the age of 16 years, the patient underwent a HSCT after conditioning with Treosulfan, Fludarabine, Thiotepa, Rituximab and Graphalon ® anti-thymocyte globulins. The intensive transfusion program required to control the cerebrovascular disease as well as the recurrent VOCs constituted the main indication for HSCT. Due to the lack of a matched sibling donor or a matched unrelated donor, her HbSA haploidentical father was employed as a donor and an ex-vivo TCRαβ and CD19 depletion on PBSC (peripheral blood stem cell) was performed. [9] The regimenrelated toxicity included grade 4 thrombocytopenia, grade 3 anemia, grade 3 febrile neutropenia and grade 3 mucositis, all resolving completely. No post-transplant immune suppression was given and all treatments for AIH were interrupted before the beginning of conditioning. On day +35 post HSCT, the patient presented with fever, abdominal pain and anorexia; a gastric and rectal biopsy showed hystological signs of Graft-versus-Host disease (GvHD) and the patient was diagnosed with grade II acute GvHD. She received treatment with cyclosporine and extracorporeal photochemotherapy, which resulted in complete remission of symptoms within one week. Cyclosporine was continued for one month and extracorporeal photochemotherapy for 4 months. At two years post-HSCT, chimerism analysis showed a full donor hematopoiesis, no SCD manifestation occurred, cerebral vasculopathy resolved almost completely (Fig. 1b) and the patient was without any medical treatment. The patient did not experience any relapse of AIH and antinuclear and anti-smooth muscle autoantibodies were found negative two months after HSCT and thereafter.
AIH is a liver disease with a wide spectrum of manifestations, ranging from asymptomatic hypertransaminasemia to decompensated cirrhosis and acute liver failure. Its treatment usually consists of long-term immune suppression with steroids and azathioprine; however, unresponsive and severe cases may require intensive treatment including liver transplantation. [10] Our report shows that allogenic HSCT may be a cure for AIH and this finding is especially important for patients with AIH and a concomitant haematological disorder. The autoimmune disorders in patients with SCD pose diagnostic and treatment dilemmas and lead to a significant worsening in the overall health and quality of life. The Treosulfan-based conditioning regime was well tolerated without any liver toxicity and resulted in a stable engraftment notwithstanding the employment of a non-conventional haploidentical donor. In particular, the haploidentical HSCT for our patient was performed with a TCRαβ and CD19 deplete PBSC graft without post transplant immune suppression, demonstrating that the HSCT itself was responsible for the cure of AIH. Moreover, the benefits of this platform include the almost universal donor availability and the absence of the toxicity associated with the use of calcineurin inhibitors or other Fig. 1 MRA of intracranial arteries pre and post-HSCT. a MRA performed at the age of 11 years showing bilateral severe stenosis of the distal internal carotid arteries (arrows), proximal middle cerebral arteries (arrow heads) and their branches. b One year after HSCT, the intracranial arteries appear almost normal immune-suppressive agents. In conclusion, we suggest that the diagnosis of an autoimmune disorder in a patient with SCD might be an indication for HSCT. Further prospective trials are necessary to confirm benefits of HSCT in terms of morbidity, organ damage and need for medical treatment. 
